Brief: Veracyte's Decipher, MRD tests highlights to be presented at EAU25
19/03/2025 21:05
March 19 (Reuters) - Veracyte Inc VCYT.O: VERACYTE ANNOUNCES EIGHT ABSTRACTS HIGHLIGHTING PERFORMANCE AND CLINICAL UTILITY OF ITS DECIPHER AND MRD TESTS IN UROLOGIC CANCERS TO BE PRESENTED AT EAU25 Source text: ID:nBw92Wzx1a Further company coverage: VCYT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina